By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



345 Park Avenue
41st Floor
New York  New York  10154-0004  U.S.A.
Phone: 212-750-6700 Fax:



Gene Therapy

Company News
Genzyme Corporation (GENZ) Withdraws Bioenvision (BIVN)'s European Filing of Evoltra(R) in Elderly AML Patients Will Resubmit With New Data from Ongoing Studies 3/19/2008 11:05:27 AM
Genzyme Corporation (GENZ) Gets Bioenvision (BIVN) for $345 Million 10/23/2007 11:47:02 AM
Delaware Court Approves Bioenvision (BIVN) and Genzyme Corporation (GENZ) Joint Petition Special Meeting to be Reconvened on October 22 10/11/2007 11:24:40 AM
Bioenvision (BIVN) and Genzyme Corporation (GENZ) File Petition in Delaware Court 10/10/2007 10:25:35 AM
Bioenvision (BIVN) and Genzyme Corporation (GENZ) (Jobs) Seek to Reopen Vote on Merger 10/10/2007 7:03:08 AM
Bioenvision (BIVN) Adjourns Special Meeting of Stockholders 10/5/2007 12:21:26 PM
Bioenvision (BIVN) Final Vote to Take Place at October 5 Special Meeting of Stockholders 10/5/2007 10:41:49 AM
Genzyme Corporation (GENZ) Affirms Purchase Price for Bioenvision (BIVN) at $5.60 Per Outstanding Share 9/27/2007 10:57:13 AM
Bioenvision (BIVN) Provides Evoltra┬« (clofarabine) Regulatory Update 8/20/2007 4:29:27 PM
Bioenvision (BIVN) Says Securities Class Action Litigation Without Merit 7/27/2007 11:40:35 AM